IP Library Granted Patent US 12,653,992
Granted Patent B2
US 12,653,992 · App. 17/295,277 · Granted Jun 16, 2026

Methods and devices for treating a disease with biotherapeutics

Inventors: Jeffrey A. Shimizu (Poway, CA); Mitchell Lawrence Jones (La Jolla, CA); Mark Sasha Drlik (Victoria, CA); Iman Niknia (Victoria, CA); Nathan John Muller (Victoria, CA); Tuyen Nguyen (Victoria, CA); Christopher Loren Wahl (San Diego, CA); Edward Mudge (Cambridgeshire, GB); Nicholas Mark Salt (Cambridgeshire, GB); Nia Eleri Stevens (Cambridgeshire, GB); Stuart Robert Abercrombie (Cambridgeshire, GB); Christopher Ian Bunce (Cambridgeshire, GB); Nelson Quintana (Temecula, CA)
Assignee: BT Bidco, Inc.
A61M31/002A61K38/1796A61K38/26A61K38/28A61M11/02A61P1/04C07K16/241A61M2210/1042A61M2210/106A61M2210/1064
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,653,992
App. No.
17/295,277
Granted
Jun 16, 2026
Kind
B2
Abstract

This disclosure features methods and devices for treating diseases with orally-delivered biotherapeutics.

Claims (31)

1 . An ingestible device comprising:

a storage reservoir in a housing;

a dispensable substance in the storage reservoir;

one or more nozzles in the housing connecting into the storage reservoir, each nozzle extending through a curved sidewall of the housing;

a gas container in the housing containing a compressed gas providing an internal pressure of about 280 psig to about 390 psig; and

a piercer for piercing the gas container to release the compressed gas from the gas container the piercer exerting a force on an enteric material triggering component, the enteric material triggering component resisting the force until the device is triggered, releasing the compressed gas from the gas container after the ingestible device is ingested;

wherein the released compressed gas drives the dispensable substance into the submucosa of the gastrointestinal tract of a patient.

2 . The ingestible device of claim 1 wherein the ingestible device is configured to deliver the dispensable substance as a jet through each nozzle with a peak jet power of each jet of about one Watt to about three Watts.

3 . The ingestible device of claim 1 wherein the released compressed gas drives a sliding piston in the housing between the gas container and the storage reservoir.

4 . The ingestible device of claim 1 wherein the ingestible device is configured to provide a peak fluid pressure on the dispensable substance of about 300 psig to about 375 psig.

5 . The ingestible device of claim 1 wherein the ingestible device is configured to deliver the dispensable substance at a mean jet velocity of from about 20 m/s to about 50 m/s.

6 . The ingestible device of claim 1 wherein the ingestible device is configured to deliver the dispensable substance to tissue of the gastrointestinal tract of a patient at a peak jet force of about 0.09 N to about 0.15 N.

7 . The ingestible device of claim 1 wherein the device is configured to release a dispensable substance volume of 50 microliters to 500 microliters.

8 . The ingestible device of claim 1 wherein one or more of the nozzles has a nozzle diameter of 0.25 millimeters to 0.45 millimeters.

9 . The ingestible device of claim 1 wherein the device is configured to release a dispensable substance volume of 200 microliters to 400 microliters.

10 . An ingestible device comprising:

a storage reservoir in a housing;

a dispensable substance in the storage reservoir;

one or more nozzles connecting into the storage reservoir, each nozzle extending through a sidewall of the housing;

a gas container in the housing containing a compressed gas, the gas container configured to provide an internal pressure of about 280 psig to about 390 psig;

a sliding piston in the housing between the gas container and the storage reservoir; and

an enteric material triggering component which triggers release of the compressed gas from the gas container after the ingestible device is ingested;

wherein the internal pressure is configured to deliver the dispensable substance into the submucosa of the gastrointestinal tract of a patient.

11 . The ingestible device of claim 10 wherein the ingestible device is configured to deliver the dispensable substance as a jet through each nozzle with a peak jet power of each jet of about one Watt to about three Watts.

12 . The ingestible device of claim 10 wherein the ingestible device is configured to provide a peak fluid pressure on the dispensable substance of about 300 psig to about 375 psig.

13 . The ingestible device of claim 10 wherein the ingestible device is configured to deliver the dispensable substance at a mean jet velocity of from about 20 m/s to about 50 m/s.

14 . The ingestible device of claim 10 wherein the ingestible device is configured to deliver the dispensable substance to tissue of the gastrointestinal tract of a patient at a peak jet force of about 0.09 N to about 0.15 N.

15 . The ingestible device of claim 10 wherein the device is configured to release a dispensable substance volume of 50 microliters to 500 microliters.

16 . The ingestible device of claim 10 wherein one or more of the nozzles has a nozzle diameter of 0.25 millimeters to 0.45 millimeters.

17 . The ingestible device of claim 10 wherein the nozzles extend through a cylindrical sidewall of the housing.

18 . The ingestible device of claim 10 wherein the enteric material triggering component exerts a restraining force which prevents release of compressed gas from the gas container until it is at least partially dissolved, degraded and/or eroded after the device is ingested.

Assignments (7)
SECURITY INTEREST Recorded Aug 15, 2025
From: BT BIDCO, INC.
To: GLAS USA LLC
Reel/Frame 072473/0861 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2025
From: BIORA THERAPEUTICS, INC.
To: BT BIDCO, INC.
Reel/Frame 070688/0777 →
LIEN Recorded Mar 31, 2025
From: BIORA THERAPEUTICS, INC.
To: BT BIDCO LLC
Reel/Frame 070691/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2025
From: BIORA THERAPEUTICS, INC.
To: BT BIDCO, INC.
Reel/Frame 070633/0696 →
SECURITY INTEREST Recorded Dec 21, 2023
From: BIORA THERAPEUTICS, INC.
To: GLAS TRUST COMPANY LLC, AS COLLATERAL AGENT
Reel/Frame 066089/0235 →
CHANGE OF NAME Recorded May 17, 2022
From: PROGENITY, INC.
To: BIORA THERAPEUTICS, INC.
Reel/Frame 060382/0322 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2021
From: SHIMIZU, JEFFREY A.; JONES, MITCHELL LAWRENCE; DRLIK, MARK SASHA; NIKNIA, IMAN; MULLER, NATHAN JOHN; NGUYEN, TUYEN; WAHL, CHRISTOPHER LOREN; MUDGE, EDWARD; SALT, NICHOLAS MARK; STEVENS, NIA ELERI; ABERCROMBIE, STUART ROBERT; BUNCE, CHRISTOPHER IAN; QUINTANA, NELSON
To: PROGENITY, INC.
Reel/Frame 058246/0740 →
Continuity (5)
Provisional Application 62932459 · Nov 7, 2019
Provisional Application 62819513 · Mar 15, 2019
Provisional Application 62818731 · Mar 14, 2019
Provisional Application 62769496 · Nov 19, 2018
Related Publication 20220249814A1 · Aug 11, 2022
References Cited (137)
US 3057344A · Alberto · 1962 [cited by applicant]
US 3118439A · Barana · 1964 [cited by applicant]
US 3315660A · Abella · 1967 [cited by applicant]
US 3485235A · Felson · 1969 [cited by applicant]
US 4036214A · Bucalo · 1977 [cited by applicant]
US 4172446A · Bucalo · 1979 [cited by applicant]
US 4239040A · Hosoya · 1980 [cited by applicant]
US 4425117A · Hugeman · 1984 [cited by applicant]
US 4439197A · Honda · 1984 [cited by examiner]
US 4481952A · Pawelec · 1984 [cited by applicant]
US 4507115A · Kambara · 1985 [cited by applicant]
US 4522625A · Edgren · 1985 [cited by applicant]
US 4596556A · Morrow · 1986 [cited by examiner]
US 5167626A · Casper et al. · 1992 [cited by applicant]
US 5170801A · Casper · 1992 [cited by applicant]
US 5217449A · Yuda et al. · 1993 [cited by applicant]
US 5279607A · Schentag · 1994 [cited by examiner]
US 5316015A · Sinaiko · 1994 [cited by applicant]
US 5318557A · Gross · 1994 [cited by applicant]
US 5395366A · Andrea · 1995 [cited by applicant]
US 5604531A · Iddan et al. · 1997 [cited by applicant]
US 5738110A · Beal et al. · 1998 [cited by applicant]
US 5858001A · Tsals et al. · 1999 [cited by applicant]
US 5951538A · Joshi · 1999 [cited by applicant]
US 5971942A · Gu et al. · 1999 [cited by applicant]
US 6632216B2 · Houzego · 2003 [cited by applicant]
US 6884239B2 · Houzego et al. · 2005 [cited by applicant]
US 6950690B1 · Meron et al. · 2005 [cited by applicant]
US 7144366B2 · Takizawa et al. · 2006 [cited by applicant]
US 7160258B2 · Imran et al. · 2007 [cited by applicant]
US 7611480B2 · Levy · 2009 [cited by applicant]
US 7662093B2 · Gilad et al. · 2010 [cited by applicant]
US 7717862B2 · Stoltz · 2010 [cited by applicant]
US 7717874B2 · Landau et al. · 2010 [cited by applicant]
US 7763014B2 · Houzeao et al. · 2010 [cited by applicant]
US 7946979B2 · Gilad et al. · 2011 [cited by applicant]
US 8005536B2 · Imran · 2011 [cited by applicant]
US 8216130B2 · Glukhovsky et al. · 2012 [cited by applicant]
US 8360976B2 · Imran · 2013 [cited by applicant]
US 8597279B2 · Dijksman et al. · 2013 [cited by applicant]
US 8626268B2 · Adler · 2014 [cited by applicant]
US 8696602B2 · Semler et al. · 2014 [cited by applicant]
US 8740774B2 · Takizawa et al. · 2014 [cited by applicant]
US 8809271B2 · Imran · 2014 [cited by applicant]
US 8926526B2 · Shuck · 2015 [cited by applicant]
US 8998881B2 · Gilbert · 2015 [cited by examiner]
US 9072834B2 · Vogt · 2015 [cited by applicant]
US 9456737B2 · Pascal · 2016 [cited by applicant]
US 9511121B2 · Imran · 2016 [cited by applicant]
US 10172598B2 · Amoako-Tuffour et al. · 2019 [cited by applicant]
US 10588608B2 · Jones et al. · 2020 [cited by applicant]
US 10632251B2 · Imran et al. · 2020 [cited by applicant]
US 10765360B2 · Euliano et al. · 2020 [cited by applicant]
US 10835152B2 · Jones et al. · 2020 [cited by applicant]
US 11007356B2 · Shimizu et al. · 2021 [cited by applicant]
US 11439802B2 · Shimizu et al. · 2022 [cited by applicant]
US 20020099310A1 · Kimchy · 2002 [cited by applicant]
US 20020198470A1 · Imran et al. · 2002 [cited by applicant]
US 20040162469A1 · Imran · 2004 [cited by applicant]
US 20040199054A1 · Wakefield et al. · 2004 [cited by applicant]
US 20040253304A1 · Gross et al. · 2004 [cited by applicant]
US 20050158246A1 · Takizawa · 2005 [cited by applicant]
US 20070043320A1 · Kenany · 2007 [cited by applicant]
US 20080051635A1 · Tanaka et al. · 2008 [cited by applicant]
US 20080086079A1 · Williamson · 2008 [cited by examiner]
US 20090275923A1 · Shimizu et al. · 2009 [cited by applicant]
US 20100049012A1 · Dijksman · 2010 [cited by examiner]
US 20100049120A1 · Dijksman et al. · 2010 [cited by applicant]
US 20100063486A1 · Diiksman et al. · 2010 [cited by applicant]
US 20100324381A1 · Glukhovskv et al. · 2010 [cited by applicant]
US 20110046458A1 · Pinedo · 2011 [cited by applicant]
US 20110087155A1 · Uhland et al. · 2011 [cited by applicant]
US 20110092959A1 · Zou et al. · 2011 [cited by applicant]
US 20110106063A1 · Diiksman et al. · 2011 [cited by applicant]
US 20120136209A1 · Kostenich et al. · 2012 [cited by applicant]
US 20120208755A1 · Leung · 2012 [cited by applicant]
US 20130172257A1 · Imran · 2013 [cited by applicant]
US 20150011874A1 · Amoaka-Tuffour et al. · 2015 [cited by applicant]
US 20150051589A1 · Sako et al. · 2015 [cited by applicant]
US 20150065926A1 · Nakamura et al. · 2015 [cited by applicant]
US 20150209411A1 · Berenbaum et al. · 2015 [cited by applicant]
US 20160213234A1 · Poon · 2016 [cited by applicant]
US 20160235663A1 · Zou et al. · 2016 [cited by applicant]
US 20160375232A1 · Kugler et al. · 2016 [cited by applicant]
US 20170050006A1 · Imran et al. · 2017 [cited by applicant]
US 20170106099A1 · Bellinger et al. · 2017 [cited by applicant]
US 20170246438A1 · Aran · 2017 [cited by examiner]
US 20170296092A1 · Jones et al. · 2017 [cited by applicant]
US 20180049725A1 · Jones et al. · 2018 [cited by applicant]
US 20180052084A1 · Jones et al. · 2018 [cited by applicant]
US 20180070857A1 · Jones et al. · 2018 [cited by applicant]
US 20180160950A1 · Rabinovitz et al. · 2018 [cited by applicant]
US 20180279908A1 · Jones et al. · 2018 [cited by applicant]
US 20180318496A1 · Zou et al. · 2018 [cited by applicant]
US 20190083073A1 · Amoaka-Tuffour et al. · 2019 [cited by applicant]
US 20190388502A1 · Corvari · 2019 [cited by applicant]
US 20200038268A1 · Shrapnel · 2020 [cited by applicant]
US 20200094031A1 · Jones et al. · 2020 [cited by applicant]
US 20200245897A1 · Jones et al. · 2020 [cited by applicant]
US 20200308268A1 · Imran · 2020 [cited by applicant]
US 20200316352A1 · Aran et al. · 2020 [cited by applicant]
US 20210015398A1 · Jones et al. · 2021 [cited by applicant]
US 20210093248A1 · Euliano et al. · 2021 [cited by applicant]
US 20210161805A1 · Zou et al. · 2021 [cited by applicant]
US 20220072286A1 · Bonner et al. · 2022 [cited by applicant]
US 20220080115A1 · Traverso et al. · 2022 [cited by applicant]
CN 1856290B · 2006 [cited by applicant]
CN 108784634A · 2018 [cited by applicant]
DE 19801573A1 · 1999 [cited by applicant]
EP 1530950A1 · 2005 [cited by applicant]
EP 2201938A1 · 2010 [cited by applicant]
EP 2515992B1 · 2012 [cited by applicant]
JP 2005073888A · 2005 [cited by applicant]
JP 2008500876A · 2008 [cited by applicant]
WO WO0145789A2 · 2001 [cited by applicant]
WO WO2008014439A2 · 2008 [cited by applicant]
WO WO2008053396A2 · 2008 [cited by applicant]
WO 2009104110A1 · 2009 [cited by applicant]
WO WO2013003824A1 · 2013 [cited by applicant]
WO 2018049133A1 · 2018 [cited by applicant]
WO WO2018183934A1 · 2018 [cited by applicant]
WO 2018213588A1 · 2018 [cited by applicant]
WO 2020041774A1 · 2020 [cited by applicant]
WO 2020157324A1 · 2020 [cited by applicant]
WO 2020160399A1 · 2020 [cited by applicant]
WO 2021119482A1 · 2021 [cited by applicant]
Moroz, Elena, Simon Matoori, and Jean-Christophe Leroux. “Oral delivery of macromolecular drugs: Where we are after almost 100 years of attempts.” Advanced drug delivery reviews 101 (2016): 108-121. [cited by applicant]
Caffarel-Salvador, Ester, et al. “Oral delivery of biologics using drug-device combinations.” Current opinion in pharmacology 36 (2017): 8-13. [cited by applicant]
Trietley et al.—“Albiglutide (Tanzeum) for Diabetes Mellitus”, Steps, New Drug Reviews, Apr. 15, 2017 (Year: 2017). [cited by applicant]
Wang, Xing-Chun. “Effects of Glucagon-like Peptide-1 Receptor Agonists on Non-Alcoholic Fatty Liver Disease and Inflammation.” World Journal of Gastroenterology, vol. 20, No. 40, Oct. 28, 2014, p. 14821., doi: 10.3748/w… [cited by applicant]
Marso, Steven P etal. “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” The New England Journal of Medicine, Nov. 10, 2016. (Year: 2016). [cited by applicant]
Ambery P, Parker et al. “MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study”. Lancet. Ju… [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/062261; Date of Mailing: Apr. 9, 2020; 16 pages. [cited by applicant]
Examination Report No. 1 for Australian Application No. 2019383976; Date of Mailing: Jun. 25, 2024; 5 pages. [cited by applicant]
Examination Report No. 2. for Australian Application No. 2019383976; Date of Mailing: Jan. 20, 2025; 5 pages. [cited by applicant]
Office Action in Japanese Application No. 2024-073391; Date of Mailing: Dec. 24, 2024; 2 pages. [cited by applicant]
Notice of Preliminary Rejection of Korean Application No. 10-2021-7018504; Date of Mailing: Mar. 20, 2025, 1 page. [cited by applicant]